04 Feb Phase 3 SEQUOIA Trial: Zanubrutinib PFS at 72 Months in Treatment Naïve CLL and SLL

Chronic lymphocytic leukemia, or CLL, and small lymphocytic lymphoma, or SLL, are chronic B cell cancers that often need long term treatment. Many patients are older at diagnosis or have other medical conditions, so the choice of first line therapy is important. Over time the goal is not only to control disease but also to preserve quality of life while keeping side effects manageable.

Targeted therapies have changed how CLL and SLL are treated. Bruton tyrosine kinase (BTK) inhibitors are now commonly used because they offer oral treatment and avoid traditional chemotherapy. Zanubrutinib is a covalent BTK inhibitor that has been studied a lot in the frontline setting. Long term results from the SEQUOIA zanubrutinib study phase 3 PFS data give useful insight into how this approach performs over time compared with chemoimmunotherapy.

Study design and patient cohorts

SEQUOIA is a global, open label, phase 3 study done across many countries and centers. It enrolled adults with untreated CLL or SLL who were not suitable for fludarabine based chemoimmunotherapy. Patients were grouped by key risk factors, including IGHV mutation status and disease stage, which mirrors real world practice.

The study used separate cohorts to address different risk groups. In the randomized cohort, patients without deletion 17p got either continuous zanubrutinib or fixed duration bendamustine plus rituximab, often called BR. This gave a direct comparison between a BTK inhibitor and a common chemoimmunotherapy regimen. In a separate high risk cohort, patients with del(17p) received zanubrutinib monotherapy. That single arm group provides long term data for patients who historically do less well with chemo based approaches.

This layout helps clinicians see how efficacy and safety play out across both standard risk and high risk patients in the frontline setting.

6 year efficacy and progression free survival

The 6 year analysis focuses on progression free survival at about 72 months. In the randomized cohort without del(17p), long term follow up shows a clear separation of the PFS curves favoring zanubrutinib compared with BR. Median PFS was not reached with zanubrutinib at six years while patients in the BR arm experienced earlier progression or the need for additional therapy. These results suggest durable disease control with continuous BTK inhibition in treatment naive CLL and SLL.

In the del(17p) cohort, zanubrutinib monotherapy is linked with favorable long-term outcomes. Many patients continue to show durable responses and ongoing survival at six years. Because this cohort is single arm, direct in study comparisons are not possible, but the long follow up gives important insight into outcomes for a group that often fares poorly with chemoimmunotherapy.

Full numerical outcomes, including hazard ratios, subgroup breakdowns, and survival curves, are available in the original SEQUOIA abstracts and congress materials.

Adding context from indirect comparisons

SEQUOIA does not directly compare zanubrutinib with some other BTK inhibitors or combination regimens. To help fill that gap, indirect analyses have been done that adjust for differences between studies. One recent paper in Blood Advances used a matching adjusted indirect comparison to compare zanubrutinib results from SEQUOIA with outcomes for acalabrutinib plus venetoclax from another frontline study. After matching baseline factors, zanubrutinib showed numerically favorable estimates of investigator assessed progression free survival in the matched groups.

These indirect methods have limits. They cannot replace randomized trials and they can be affected by differences in patient selection and outcome assessment. Still, they provide helpful context when clinicians must weigh options across studies. Network analyses looking at multiple BTK inhibitor trials also offer perspective, though methods and assumptions vary. For practical decisions, indirect comparisons are best used as one piece of evidence alongside trial details, safety profiles, comorbidities, and patient preferences.

High risk del(17p) disease

Patients with del(17p) tend to have worse outcomes with chemoimmunotherapy. The separate del(17p) cohort in SEQUOIA helps show how zanubrutinib performs in this high-risk group. The 6 year data show continued disease control for many patients and survival outcomes that remain consistent over time.

In everyday practice, clinicians combine SEQUOIA results with findings from other BTK inhibitor studies and real-world data when deciding treatment for del(17p) patients. Tolerability, comorbidities, and patient goals are important in choosing a plan.

Safety and tolerability over long term follow-up

Safety matters when a treatment may be given for years. Across SEQUOIA, zanubrutinib showed a safety profile in line with expectations for BTK inhibitors. Common events include infections, low blood counts, bleeding events, high blood pressure, and atrial arrhythmias. These were monitored over time and the six year follow up provides more practical information on ongoing management.

In the BR group, adverse events were typical for chemoimmunotherapy, including myelosuppression and treatment related infections. For patients who stay on BTK inhibitors for many years, careful monitoring and supportive care are important to keep quality of life acceptable.

Role in frontline CLL and SLL care

For patients who are treatment naive, the aim is durable disease control with acceptable side effects. SEQUOIA shows how a BTK inhibitor strategy can give sustained PFS benefit over six years in patients without del(17p) while also offering meaningful long-term outcomes in those with del(17p).

Clinicians typically look at SEQUOIA together with other BTK inhibitor trials, indirect comparisons, and real-world evidence when deciding on sequencing, switching after intolerance, or choosing between covalent and noncovalent agents. This broader view helps keep treatment choices aligned with both efficacy and safety needs.

Ongoing evidence and future directions

Long term trials like SEQUOIA support ongoing clinical discussion about frontline treatment options for CLL and SLL. As more data come from SEQUOIA and other studies, clinicians will have better information to refine use of zanubrutinib across patient groups and lines of therapy.

Where to find more information

For full numerical results, survival curves, and subgroup data, see the SEQUOIA zanubrutinib study phase 3 PFS data listed in the References section below, along with related congress abstracts and peer reviewed publications. Additional context from indirect comparison analyses is also included in the references.

References

1. https://beonemedaffairs.com/us/congress-resources/ash-2025/phase-3-sequoia-6-year-long-term-data-of-zanubrutinib-vs-bendamustine-plus-rituximab-in-tn-cll-sll/
2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025018536/566249/An-Indirect-Comparison-of-Zanubrutinib-vs
3. https://pubmed.ncbi.nlm.nih.gov/41587482/

—-

The information on MedicalResearch.com is provided for educational purposes only and may not be up to date. It is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. Products, services and provider are not warranted or endorsed.

Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on February 4, 2026 by Marie Benz MD FAAD